Processa Pharmaceuticals, Inc. Notes Payable, Current
Processa Pharmaceuticals, Inc. (PCSA) had Notes Payable, Current of $144.89 thousand as of 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current › Long-Term Debt, Current Maturities › Notes and Loans Payable, Current › Notes Payable, Current
us-gaap:NotesPayableCurrent · last filed 2022-03-30
- 2021-03-31: Notes Payable, Current $144.89K.
- 2020-12-31: Notes Payable, Current $117.57K.
- 2020-09-30: Notes Payable, Current $90.33K.
- 2020-06-30: Notes Payable, Current $72.20K.
| Period end | Notes Payable, Current |
|---|---|
| 2021-03-31 | $144.89K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $117.57K 10-K · filed 2022-03-30 |
| 2020-09-30 | $90.33K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $72.20K 10-Q · filed 2020-08-05 |
| 2017-06-30 | $1.04M 10-Q · filed 2017-10-04 |
| 2017-03-31 | $962.36K 10-Q · filed 2017-10-04 |
| 2016-12-31 | $962.36K 10-Q · filed 2017-11-20 |
| 2016-09-30 | $962.36K 10-Q · filed 2017-09-08 |
| 2016-06-30 | $962.36K 10-Q · filed 2017-08-30 |
| 2016-03-31 | $962.36K 10-Q · filed 2017-08-07 |
| 2015-12-31 | $947.36K 10-K · filed 2017-09-25 |
| 2015-09-30 | $947.36K 10-Q · filed 2015-12-01 |
| 2015-06-30 | $908.36K 10-Q · filed 2015-08-19 |
| 2015-03-31 | $630.00K 10-Q · filed 2015-05-15 |
| 2014-12-31 | $160.00K 10-Q · filed 2015-12-01 |
| 2014-09-30 | $250.00K 10-Q · filed 2014-11-13 |
| 2014-06-30 | $250.00K 10-Q · filed 2014-08-19 |
| 2014-03-31 | $500.00K 10-Q · filed 2014-05-14 |
| 2013-12-31 | $590.00K 10-Q · filed 2014-11-13 |
| 2013-06-30 | $990.09K 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |